|
注册号: Registration number: |
ChiCTR2600125090 |
|
最近更新日期: Date of Last Refreshed on: |
2026-05-21 10:58:06 |
|
注册时间: Date of Registration: |
2026-05-21 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
右美托咪定联合星状神经节阻滞对术后睡眠的影响:一项探索性、开放标签、随机对照临床研究 |
|
Public title: |
Effect of Dexmedetomidine Combined with Stellate Ganglion Blockade on Postoperative Sleep: An Exploratory, Open-Label, Randomized Controlled Clinical Study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
右美托咪定联合星状神经节阻滞对术后睡眠的影响:一项探索性、开放标签、随机对照临床研究 |
|
Scientific title: |
Effect of Dexmedetomidine Combined with Stellate Ganglion Blockade on Postoperative Sleep: An Exploratory, Open-Label, Randomized Controlled Clinical Study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘汶 |
研究负责人: |
陈受琳 |
|
Applicant: |
Wen Liu |
Study leader: |
Shoulin Chen |
|
申请注册联系人电话: Applicant telephone: |
+86 18 829 677 6158 |
研究负责人电话:
Study leader's |
+86 133 6700 0367 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
lw1504420376@163.com |
研究负责人电子邮件: Study leader's E-mail: |
ndefy98008@ncu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国江西省南昌市东湖区民德路1号 |
研究负责人通讯地址: |
中国江西省南昌市东湖区民德路1号 |
|
Applicant address: |
No. 1, Minde Road, Donghu District, Nanchang City, Jiangxi Province, China |
Study leader's address: |
No. 1, Minde Road, Donghu District, Nanchang City, Jiangxi Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南昌大学第二附属医院麻醉科 |
||
|
Applicant's institution: |
Department of Anesthesiology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University |
||
|
研究负责人所在单位: |
南昌大学第二附属医院麻醉科 |
||
|
Affiliation of the Leader: |
Department of Anesthesiology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
I-医研伦审[2026]第(026)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南昌大学第二附属医院生物医学研究伦理委员会 |
||
|
Name of the ethic committee: |
IBR EC of the second uflllated hospital of Nanchang university |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-03-30 00:00:00 | ||
|
伦理委员会联系人: |
程学新 |
||
|
Contact Name of the ethic committee: |
Xuexin Cheng |
||
|
伦理委员会联系地址: |
中国江西南昌市民德路1号 |
||
|
Contact Address of the ethic committee: |
No. 1 Minde Road, Donghu District, Nanchang City, Jiangxi Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 791 8620 9562 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
南昌大学第二附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国江西省南昌市东湖区民德路1号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 1, Minde Road, Donghu District, Nanchang City, Jiangxi Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
NA |
||||||||||||||||||||||
|
研究疾病: |
术后睡眠障碍 |
||||||||||||||||||||||
|
Target disease: |
Postoperative Sleep Disorders |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究旨在评估围术期右美托咪定联合星状神经节阻滞对择期手术患者术后睡眠障碍发生率影响; 右美托咪定联合星状神经节阻滞是否有效减少术后焦虑抑郁和术后疼痛的发生。 |
||||||||||||||||||||||
|
Objectives of Study: |
The primary objective of this study was to evaluate the effect of perioperative dexmedetomidine combined with stellate ganglion block on the incidence of postoperative sleep disturbance in patients undergoing elective surgery.The secondary objective was to determine whether this combined intervention could reduce postoperative anxiety, depression, and pain. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.严重心脏传导系统疾病或明显心功能不全(如病态窦房结综合征、HR<50次/分的窦性心动过缓、Ⅱ度及以上房室传导阻滞、NYHA III级及以上心功能不全等); 2.经精神科明确诊断的重度精神或神经系统疾病; 3.合并可能影响星状神经节阻滞安全性的疾病,如甲状腺功能亢进症、嗜铬细胞瘤或巨大甲状腺肿(III度及以上,伴气管受压、移位或狭窄者); 4.肝内胆管结石需行肝切除和(或)复杂胆道重建者; 5.既往重大肝胆手术史; 6.凝血功能障碍、局部皮肤感染、青光眼等; 7.近期使用镇静催眠药物或右美托咪定; 8.或其他被认为不适合参加研究的情况 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Severe cardiac conduction system disease or significant cardiac dysfunction, such as sick sinus syndrome, sinus bradycardia with heart rate <50 beats/min, second-degree or higher atrioventricular block, or New York Heart Association (NYHA) class III or higher heart failure; 2.Severe psychiatric or neurological disorders confirmed by a psychiatrist; 3. Comorbid conditions that may compromise the safety of stellate ganglion block, including hyperthyroidism, pheochromocytoma, or large goiter (grade III or above) with tracheal compression, deviation, or stenosis; 4 .Intrahepatic bile duct stones requiring hepatic resection and/or complex biliary reconstruction; 5. History of major hepatobiliary surgery; 6. Coagulation disorders, local skin infection at the puncture site, glaucoma, or other relevant conditions; 7. Recent use of sedative-hypnotic medications or dexmedetomidine; 8. Any other condition deemed by the investigators to render the patient unsuitable for participation in the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-06-01 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-06-01 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机序列由一名独立研究人员使用SPSS统计软件生成的随机数字表产生,并采用不透明密封信封进行分配隐藏。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Eligible participants who provided written informed consent were randomly allocated to study groups using sealed, opaque envelopes containing random numbers generated by statistical software. Allocation was performed by the anesthesiologist responsible for the stellate ganglion block immediately before the intervention. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
评估者设盲 |
|
Blinding: |
Blinding of evaluators |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
NA |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
Case Record Form |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
This study will develop a standardized Case Report Form (CRF). The CRF will be designed in accordance with the study protocol and will cover data from the entire study process, including subject screening, baseline information, visits during the treatment period, efficacy assessments, and safety records. The CRF will be subject to version control, and its completion will follow "Standard Operating Procedures" to ensure that any data modifications are documented (if modified, the changes must be crossed out, signed, and dated), thereby guaranteeing the authenticity, accuracy, and traceability of the raw data. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |